Challenges and opportunities in metastatic breast cancer treatments: Nano-drug combinations delivered preferentially to metastatic cells may enhance therapeutic response.

Yu, Jesse; Mu, Qingxin; Fung, Millie; Xu, Xiaolin; Zhu, Linxi; Ho, Rodney J Y

Yu, Jesse; Mu, Qingxin; Fung, Millie; Xu, Xiaolin; Zhu, Linxi; Ho, Rodney J Y.

Afiliação

Yu J; Department of Pharmaceutics, University of Washington, Seattle, WA 98195, USA.
Mu Q; Department of Pharmaceutics, University of Washington, Seattle, WA 98195, USA.
Fung M; Department of Pharmaceutics, University of Washington, Seattle, WA 98195, USA.
Xu X; Department of Pharmaceutics, University of Washington, Seattle, WA 98195, USA.
Zhu L; Department of Pharmaceutics, University of Washington, Seattle, WA 98195, USA.
Ho RJY; Department of Pharmaceutics, University of Washington, Seattle, WA 98195, USA; Department of Bioengineering, University of Washington, Seattle, WA 98195, USA. Electronic address: rodneyho@uw.edu.

Pharmacol Ther ; 236: 108108, 2022 08.

Article em En | MEDLINE | ID: mdl-34999182

Assuntos

Neoplasias da Mama; Nanopartículas; Neoplasias da Mama/tratamento farmacológico; Linhagem Celular Tumoral; Feminino; Humanos; Nanopartículas/uso terapêutico; Nanotecnologia/métodos; Recidiva Local de Neoplasia

Palavras-chave

Combination therapy; Drug delivery; Metastatic breast cancer; Nanoparticles; Targeted therapy

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Nanopartículas Limite: Female / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google